Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are new oral antidiabetic drugs that reduce hyperglycemia by promoting urinary glucose excretion. Glycosuria produced by SGLT2 inhibitors is associated with weight loss, mainly due to reduced fat volume. We investigated the effects of em...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Diabetol Metab Syndr
Main Authors: Jojima, Teruo, Tomotsune, Takanori, Iijima, Toshie, Akimoto, Kazumi, Suzuki, Kunihiro, Aso, Yoshimasa
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2016
Fag:
Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4960737/
https://ncbi.nlm.nih.gov/pubmed/27462372
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-016-0169-x
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker